Johnson & Johnson submits tapentadol IR NDA

Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for tapentadol immediate-release (IR) tablets to treat moderate-to-severe acute pain. The mu opioid receptor agonist and norepinephrine reuptake in...